ScholarIQanswers from OpenAlex & ORCID
Paul Lorigan
ResearcherPublications, citations & collaboration network
Paul Lorigan is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Paul Lorigan have?
ScholarIQindexed works
Paul Lorigan has 688 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Paul Lorigan have?
ScholarIQcitation count
Paul Lorigan has 64,435 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Paul Lorigan?
ScholarIQh-index
Paul Lorigan has an h-index of 88 in OpenAlex.
What is the i10-index of Paul Lorigan?
ScholarIQi10-index
Paul Lorigan has an i10-index of 282 in OpenAlex.
What is the ORCID of Paul Lorigan?
ScholarIQorcid
The ORCID for Paul Lorigan is on the source record.
What is the OpenAlex record for Paul Lorigan?
ScholarIQopenalex
The OpenAlex for Paul Lorigan is on the source record.
What are the most-cited papers on Paul Lorigan?
ScholarIQmost cited works
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck, Alexander Luft, Aleksandra Szczęsna, Libor Havel, Sang-We Kim, Wallace Akerley, M. Catherine Pietanza, Yi‐Long Wu, Christoph Zielinski, Michael J. Thomas, Enriqueta Felip, Kathryn A. Gold, Leora Horn, Joachim G.J.V. Aerts, Kazuhiko Nakagawa, Paul Lorigan, Anne Pieters, Teresa Kong Sanchez, Justin Fairchild, David R. Spigel
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
Ulrich Keilholz, P.A. Ascierto, Reinhard Dummer, Caroline Robert, Paul Lorigan, Alexander C. J. van Akkooi, Ana Arance, Christian U. Blank, V. Chiarion Sileni, Marco Donia, Mark B. Faries, Caroline Gaudy‐Marqueste, Helen Gogas, Jean‐Jacques Grob, Matthias Gückenberger, John B.A.G. Haanen, Andrew Hayes, Christoph Höeller, Célèste Lebbé, Iwona Ługowska, Mario Mandalà, Iván Márquez‐Rodas, Paul Nathan, Bart Neyns, Roger Olofsson Bagge, Susana Puig, Piotr Rutkowski, Bastian Schilling, Vernon K. Sondak, Hussein A. Tawbi, Alessandro Testori, Olivier Michielin